

# Prior Authorization Checklist

These considerations are intended to clarify the prior authorization (PA) process for patients who have been prescribed ZUSDURI™ (mitomycin) for intravesical solution.

## PA Checklist

PA requirements vary by health plan. In order for us to better assist you, please be prepared to include the following information when you submit the PA. After the benefits investigation is completed, UroGen Support will provide you with a list of specific PA requirements and appropriate forms.

- 1** Most PA forms will require the following information:
  - ☐ Patient information, including date of birth and insurance policy number
  - ☐ Provider and facility information, including name, NPI number, and tax ID number
  - ☐ Date of service
  - ☐ Relevant procedure codes for services/products to be performed/provided
  - ☐ Setting of care
- 2** Some PA forms may require a letter of medical necessity. Please visit [UroGenSupport.com](https://UroGenSupport.com) for a sample letter you can use to advocate for your patients.
- 3** PA approval for ZUSDURI may require specific information, such as:
  - ☐ ZUSDURI indication statement
  - ☐ ZUSDURI Prescribing Information
  - ☐ Documentation of LG-IR-NMIBC diagnosis
  - ☐ Documentation of previous therapy(ies), including length of therapy and reason for discontinuation
  - ☐ FDA approval letter

PA requirements vary by health plan. Please contact the patient's health plan for specific PA requirements to ensure efficient and timely review. Failure to obtain a PA can result in nonpayment by the plan. Please check your contract for any policy exclusions.

Prior to submission, please keep track of dates and methods of communication (verbal and written), record the names of insurance contacts and reviewers with whom you speak, and summarize conversations and written documents issued by the insurer.



**If you have any questions, or need guidance,  
please call 833-UROGEN1 (833-876-4361)  
or visit [UROGENSUPPORT.com](https://UROGENSUPPORT.com).**

FDA, US Food and Drug Administration; LG-IR-NMIBC, low-grade intermediate-risk non-muscle invasive bladder cancer; NPI, National Provider Identifier.